Shamburg News · 8-K filed Oct 26, 2026, 5:00 PM EDT

DataMEDS AI Enters Non-Binding LOI to Acquire QLPM IP and Tollo Health Controlling Interest

MEDS · DataMeds AI, Inc.

  • Material agreement
  • Acquisition
  • Reg FD disclosure
  • Materiality: high

On October 21, 2026, DataMEDS AI, Inc. entered into a non-binding Second Amended and Restated Letter of Intent dated October 19, 2026, with EOS Technology Holdings, Scilex Holding Company, Datavault AI Inc., HealthBridge Advisors, LLC, Tollo Health, Inc., and REBOOT Health AI, Inc., superseding the prior Term Sheet and First A&R LOI. The proposed transaction contemplates acquiring QLPM intellectual property, expanding the PharmacyChain license with Datavault AI, and acquiring a controlling interest in Tollo Health, LLC in exchange for Company common stock, with EOS, Scilex, Datavault, Fortitude Advisors, HBA, THI and REBOOT expected to own approximately 89.5% of the common stock post-closing. The non-binding LOI is subject to definitive agreements, stockholder and Nasdaq approvals, and includes exclusivity through November 30, 2026 and reimbursement of up to $250,000 in legal fees.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 9.01, accession 0001493152-26-048573.

Written from the filing by Shamburg Markets. Figures are as reported by the company.